Target intelligence / Profile preview

Myelin proteolipid protein (PLP)

Target
PLP
Molecular classification
Other
01

Overview

Myelin proteolipid protein (PLP), encoded by the PLP1 gene, is the most abundant transmembrane protein in the central nervous system myelin sheath, playing a critical role in the compaction, stabilization, and maintenance of myelin. In the context of multiple sclerosis (MS), PLP and its immunodominant peptide fragments (such as PLP 139-151) serve as major autoantigens that trigger autoreactive T-cell and B-cell responses, leading to demyelination and neurodegeneration. Consequently, PLP peptides are utilized in antigen-specific tolerization therapies—such as peptide-coupled red blood cells (TOL001) or transdermal skin patches—to selectively desensitize the immune system and restore tolerance without causing broad immunosuppression. Additionally, mutations or duplications of the PLP1 gene lead to Pelizaeus-Merzbacher disease (PMD), a severe, fatal leukodystrophy characterized by hypomyelination due to the accumulation of toxic, misfolded PLP. Therapeutic strategies for PMD include the use of antisense oligonucleotides (such as ION356) to suppress PLP1 expression and mitigate proteotoxic stress in oligodendrocytes.

Other names
Proteolipid protein 1PLP1LipophilinProteolipid protein peptidesPLP peptidesMyelin proteolipid protein peptidesDM20
02

Mechanism of action

Antisense oligonucleotide-mediated knockdown of PLP1 pre-mRNA to reduce toxic mutant PLP1 protein expression; Antigen-specific immune tolerance induction (tolerization) to suppress autoreactive T-cell responses against myelin

03

Biological functions

Immune responseOther
04

Disease associations

Neurodegenerative diseaseInflammationOther
05

Safety considerations

Anaphylaxis or hypersensitivity reactions to peptide administrationRisk of inducing immune activation or disease exacerbationOff-target effects of antisense oligonucleotidesIncomplete knockdown or cell-type-specific knockdown efficiency of ASOsIntrathecal administration risks
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Neurofilament light chainPLP-specific T-cell proliferative responseAnti-PLP antibodiesGadolinium-enhancing lesions on brain MRIPLP1 gene duplication

Beyond the preview

Go deeper on Myelin proteolipid protein (PLP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myelin proteolipid protein (PLP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call